Contribution of genetic polymorphisms of the CYP3A4, CYP3A5 and MDR1 genes to cyclosporine disposition

Chinese Pharmacological Bulletin

Volumn 21, Issue 3, 2005, Pages 257-261

  Hu, Yong Fang ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cyclosporine; CYP3A4; CYP3A5; Disposition; MDR1

Indexed keywords

COMPLEMENTARY DNA; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE FREQUENCY; GENETIC POLYMORPHISM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 22344432565     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mahalati K, Belitsky P, Sketris I et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve[J]. Transplantation, 1999,68(1):55-62.
2. Kahan BD, Keown P, Levy GA et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice[J]. Clin Ther, 2002,24(3):330-50, discussion 329.
3. Keown PA. New concepts in cyclosporine monitoring[J]. Curr Opin Nephrol Hypertens, 2002,11(6):619-29.
4. Evans WE, McLeod HL. Pharmacogenomics-Drug disposition, drug targets and side effect[J]. N Engl J Med, 2003,348(6):538 -49.
5. Weinshilbourn R. Inheritance and drug response[J]. N Engl J Med, 2003,348(6):529-37.
6. Zhu B, Liu ZQ, Chen GL et al. The distribution and gender difference of CYP3 A activity in Chinese subjects[J]. Br J Clin Pharmacol, 2003,55(3):264-9.
7. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001,27(4):383-91.
8. Lamba JK, Lin YS, Schuetz EG et al. Genetic contribution to variable human CYP3A - mediated metabolism[J]. Adv Drug Deliv Rev, 2002,54(10):1271-94.
9. Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in Chinese[J]. Drug Metab Dispos, 2001,29(3):268-73.
10. Fukushima-Uesaka H, Saito Y, Watanabe H et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J]. Hum Mutat, 2004,23(1):100-8. (Mutation in Brief#681).
11. Xie HG, Wood AJ, Kim RB et al. Genetic variability in CYP3A5 and its possible consequences[J]. Pharmacogenomics 2004,5 (3):243-72.
12. Aoyama T, Yamano S, Waxman DJ et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver, cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine[J]. J Biol Chem, 1989,264(18):10388-95.
13. Turgeon DK, Normolle DP, Leichtman AB et al. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients[J]. Clin Pharmacol Ther, 1992,52(5):471-8.
14. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans[J]. Clin Pharmacol Ther, 2001,70(2):189-99.
15. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporin A and FK506[J]. J Biol Chem, 1993,268 (9):6077-80.
16. Lown KS, Mayo RR, Leichtman AB et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclpsporine[J]. Clin Pharmacol Ther, 1997,62(3):248-60.
17. Min DI, Ellingrod VL. Association of the CYP3 A4 * 1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in the healthy subjects[J]. Ther Drug Monit, 2003,25(3):305-9.
18. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects [J]. Ther Drug Monit, 2002,24(3):400-4.
19. von Ahsen N, Richter M, Grupp C et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentration or rejection incidence in stable renal transplant recipients[J]. Clin Chem, 2001,47(6):1048-52.
20. Rivory LP, Qin H, Clarke SJ et al. Frequency of cytochrome P450 3 A4 variant genetype in transplantation population and lack of association with cyclosporin clearance[J]. Eur J Clin Pharmacol, 2000,56(5):395-8.
21. Haufroid V, Mourad M, van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients[J]. Pharmacogenetics, 2004,14(3):147 -54.
22. Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineur ininhibitors cyclosporine and tacrolimus[J]. Clin Pharmacol Ther, 2003,74(3):245-54.
23. Yates CR, Zhang W, Song P et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients[J]. J Clin Pharmacol, 2003,43(6):555 -64.
24. Anglicheau D, Thervet E, Etienne I et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharamacokinetics after renal transplantation[J]. Clin Pharmacol Ther, 2004,75(5):422-33.
25. Chowbay B, Cumaraswamy S, Cheng YB et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients [J]. Pharmacogenetics, 2003,13(2):89-95.